Thank you for your interest. Give here your contact details and you'll receive an email with the pdf file you request.
Sign up to our monthly newsletter to receive our news.
A new unit for the CHU Liège Toxicology Department to better serve the pharma sector
ATC is a contract research organisation (CRO) with its facilities based within the CHU Liege. Its flexibility and multidisciplinary expertise, its access to patients via its privileged contacts with CHU medical departments and its links to ULg research centres are key factors determining its consistent success over the last third of a century.
As of 1 January 2017, the services offered to customers have taken on a new dimension.
ATC was historically made up of two units: the Pre-Clinical and Analytic (PCA) Unit specialised in the bio-analysis of physiologically active substances and the conduct of pre-clinical studies (in vitro & in vivo); and the Clinical Pharmacology Unit, specialised in carrying out clinical trials (Phase 0, I, IIa or Early Phase).
The PCA unit has now become part of the CHU Liège Toxicology Department (itself part of the Unilab Lg), headed by Prof. Corinne Charlier. “Over time, these two departments have come to develop very similar activities, using the same high-performance technologies and both having high-qualified staff able to carry out tasks in this field in compliance with international quality standards. The synergies were obvious”, explained Prof. Charlier.
The PCA Unit is thus changing its name, and will henceforth by known as the GLP Unit for Pre-Clinical and Toxicological Analyses and Evaluations (GLP-AEPT). As indicated by its name, its mission to provide services complying with “good laboratory practice” (GLP) will be maintained and even strengthened. The new unit’s technical facilities reflect this mission: 7 coupled liquid chromatography/mass spectrometry systems, including 4 ultra-high-pressure liquid chromatography systems, 4 coupled gas chromatography/mass spectrometry systems, 2 plasma torches, and many other systems.
“The existing intense collaboration between the ATC’s Clinical Pharmacology Unit, specialised in Phase I clinical trials, and the new GLP AEPT will be strengthened by this restructuring”, said Dr. Patrice Chiap.
Moreover, integrating this unit into the Toxicology Department means that customers can now be offered a very flexible service, allowing tight deadlines, the possibility of very varied analyses, and wide-ranging expertise in the field of pharmacological, pharmacokinetic and toxicological evaluations. The scientific team is made up of pharmacists, bio-pharmacists, chemists and engineers. Each project is supervised by a study director working in close collaboration with the customer to achieve a tailor-made solution covering a wide range of services.
In collaboration with a team at the University of California at Los Angeles (UCLA), researchers from GIGA-Neurosciences have discovered a new gene responsible for a seizure syndrome called juvenile myoclonic epilepsy (JME). This discovery was made as part of an international consortium that studies genetic abnormalities responsible for epileptic diseases. It is being published this week in
The LIGHTSHEET MICROSCOPY can deliver optical sections, 3D reconstructions and timelapse movies of whole sample volumes at subcellular resolutions. The fast scan speeds and low phototoxicity of the lightsheet allow to record the development of fluorescent transgenic animals over long time periods, such as zebrafish embryos. Alternatively 3D reconstructions of fixed whole organs or whole embryos,
The researchers discovered that this cellular dialogue controls the growth of the cerebral cortex and that its impairment leads a cortical malformation previously associated with autism in mice . Their results are published in the prestigious scientific journal Cell. The cerebral cortex contains excitatory and inhibitory interneurons. The former are produced locally and move by